Big Board

Keyword
Content Ideas
Result Content Idea Research
Result Content Idea Research
1 Drug-coated devices associated with less unplanned limb revascularization: VOYAGER PAD
2 New Xarelto (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
3 New XARELTO® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
4 Top news from VIVA: Drug-coated devices, treatments for PAD and more
5 Rivaroxaban Plus Aspirin Reduced Cardiac, Limb Events in PAD After LER
6 Voyager's Arrival Bodes Well for Boston Sci's Ranger DCB
7 VOYAGER PAD: Treatment effect of rivaroxaban in PAD strongest in concomitant CAD
8 No sign of paclitaxel-related mortality risk in VOYAGER PAD cohort
9 Rivaroxaban in Peripheral Artery Disease after Revascularization
10 As 'Paclitaxelgate' Loses Steam, Experts Mull Lasting Impact for Future Trials, Practice
11 VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events
12 VOYAGER PAD: Rivaroxaban Reduces Risk in Symptomatic PAD Post Intervention
13 Results from the VOYAGER PAD Trial reported at TCT Connect
14 Post-COVID Heart Syndrome; Auto-Antibodies in COVID Clotting; CT Training
15 VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban
16 What Does VOYAGER PAD Mean for Antithrombotic Therapy?
17 Final Five Unpublished Late-Breaking Clinical Trial Results Announced at VIVA20
18 Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy
19 VOYAGER PAD: Clopidogrel Adds No Benefit to Rivaroxaban+Aspirin
20 VOYAGER PAD Subgroup Analysis: Clopidogrel Atop Rivaroxaban and Aspirin Shows No Added Benefit for PAD
21 VOYAGER-PAD
22 Paclitaxel-coated balloons: Impact on the drug-coated balloon market
23 New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy
24 ESVS Webinar concludes VOYAGER PAD data “must be received like an earthquake”
25 No Mortality Risk Associated With Paclitaxel-coated Devices Used to Treat Peripheral Artery Disease
26 William R. Hiatt, MD, on the Practice-Guiding Results of a VOYAGER-PAD Subgroup Analysis
27 Janssen Submits Application to US FDA for New Indication to Expand Use of XARELTO® (rivaroxaban) in Patients with Peripheral Artery Disease
28 Clinical Catch-Up: November 9-13
29 IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs
30 Patients with multiple revascularisations are at higher risk of acute limb ischaemia, and derive “particularly robust benefit” from Rivaroxaban
31 Phase 3 trials: XARELTO vascular dose plus aspirin in treating patients with atherosclerotic disease
32 PAD Awareness Month calls attention to amputation risks, screening, treatments
33 Rivaroxaban Reduces Adverse Limb, CV Events in Peripheral Artery Disease
34 BRIEF-Janssen Pharmaceutical Companies Says Voyager Pad Study Met Primary Efficacy, Principal Safety Endpoints
35 DAPT Plus DOAC a Loser After Lower Limb Revascularization
36 Rivaroxaban sNDA Submitted for Symptomatic Peripheral Artery Disease
37 ACC | Cardiology
38 Rivaroxaban Reduces Risk in Symptomatic Peripheral Artery Disease Post-Surgical Intervention
39 Rivaroxaban Plus Aspirin Beneficial in Symptomatic PAD After Revascularization
40 The ACC.20/WCC Sessions Are Virtually Here: A Preview
41 Janssen to Unveil Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
42 Stellarex Paclitaxel Coated Balloon Safe, Durable in PAD
43 CX 2020 LIVE: Strong support for relining peripheral arteries and rivaroxaban use for widespread atherosclerosis
44 R3 Vascular completes Series A financing
45 ACC 2020 Late-breaking Presentations | DAIC
46 Extra Ticagrelor Benefit When PAD Adds to CAD, Diabetes: THEMIS
47 SVS pilots SET app for peripheral arterial disease patients
48 New clinical data support use of 4F devices for ambulatory PAD treatment
49 ACC announces lineup for late-breaking trials
50 Ra Medical Systems announces 10 subjects have been enrolled in its DABRA trial
51 PRIZER, new multicentre PAD study, launches
52 Clean Power Provides Update on the Development of Its PowerTap Investment
53 Alucent Biomedical announces US$35 million Series B financing
54 Becton Dickinson & Co. (BDX) Q4 2020 Earnings Call Transcript
55 High level of heterogeneity found in randomised PAD trial antithrombotic regimens
56 Gene Therapy Market Growth Forecast to hit $363 million by 2022
57 American Heart Association Offers Guidance on Diabetes, Coronary Artery Disease
58 First patient enrolled in FUTURE SFA study of MagicTouch sirolimus-coated balloon
59 Cocoa a Novel Rx for Peripheral Artery Disease?
60 Rivaroxaban Plus Aspirin vs Aspirin Alone Lowers MACE in Patients With Prior PCI
61 Philips to expand its image-guided therapy portfolio through acquisition of Intact Vascular
62 The Best Yoga Mats
63 First-Ever Virtual ACC Meeting to Debut Data for Novel HF Drug
64 VICTORIA Results to Headline ACC's First-Ever Virtual Meeting
65 IN.PACT BTK: Step in the Right Direction for DCB in Below-Knee CLI
66 Wingman catheter granted expanded indication to cross CTOs in PAD
67 SVS International Lecture: Endovascular pioneer discusses new PAD therapy
68 TCT 2020: Abbott devices, TAVR systems headline late breaker lineup
69 CMS grants additional reimbursement for the Eluvia drug-eluting vascular stent system
70 Altavida 12-lb. Cooling Weighted 48'' x 72'' Blanket only $33.99 (reg. $139.99)
71 India to launch Shukrayaan Venus mission in 2024 after pandemic delays: reports
72 Announcing the TCT Connect Late-Breaking Trials and Science
73 Rivaroxaban Superior to Heparin in Preventing Blood Clots After Common Orthopedic Surgeries
74 The Take Home: ACC
75 Becton, Dickinson and Company (BDX) CEO Thomas Polen on Q4 2020 Results
76 Ra Medical Systems receives FDA IDE approval to begin pivotal atherectomy clinical study
77 Peripheral Arterial Disease
78 Philips Introduces QuickClear Mechanical Thrombectomy System for Blood Clot Removal
79 Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues
80 New guideline: ASA no longer recommended to prevent first stroke, heart disease
81 Star Trek: 10 Unpopular Opinions About Enterprise (According To Reddit)
82 CMS approves coverage for PQ Bypass TORUS 2 IDE trial
83 Annual U.S. Economic Burden of Critical Limb Ischemia Exceeds $200 Billion
84 Anatomic Burden, Ischemia Severity, and Outcomes in ISCHEMIA
85 Paclitaxel Devices in PAD: Debate Continues, but Risk 'Cannot Be Ignored'
86 Statins linked with reduced mortality in PAD patients, even when started late after diagnosis
87 CARAVAGGIO: Oral Apixaban as Good as Dalteparin for Treating Cancer-Associated Clots
88 COMPASS: Rivaroxaban Reduces CV and Limb Events in PAD
89 AHA Scientific Statement on Critical Limb Ischemia
90 A Thanksgiving sun treat: Big sunspot rotates into view
91 Positive NICE recommendation for Xarelto to prevent atherothrombotic events in CAD and PAD patients
92 Licensed indication for use of Xarelto in peripheral arterial disease
93 FDA Warns of Mortality Signal With Paclitaxel Devices in PAD
94 Peripheral arterial disease risk hinges on health factors and demographics, including race
95 SFDI promising technology for assessing patients at risk of PAD
96 Tack Endovascular System launches in the USA, first commercial use announced
97 TCT 2020: Short DAPT, Longer TAVR Outcomes, Intravascular Imaging, and More
98 CIRSE 2019: New Cook Medical paclitaxel data confirm safety of Zilver PTX
99 Implantation Technique Influences LV Remodeling After TMVR
100 Depression and peripheral arterial disease: A call to action